Clinical Phytoscience · 2016 · 65 citations · 81 references
MedicinePharmacologyToxicologyBiochemical PharmacologyClinical PharmacologyMolecular PharmacologyHepatic ImpairmentHepatic PathophysiologyHepatic ToxicityHepatotoxicity MechanismsLiver DiseaseHepatic DisordersHepatic OxidationHepatoprotective AgentsLiver Disease Effects On MetabolismLiver Toxicity MechanismsPharmacological TherapySafe Medication HandlingSilymarin Therapy
Silymarin has long been used as a hepatoprotective remedy. Chronic toxicity studies in rodents have confirmed that silymarin has a very low toxicity. These data support its history as a safe medication in hepatic diseases. In the last years, several studies expanded our understanding of the pharmacology of silymarin and its molecular mechanisms of action. These new insights may affect the handling of silymarin in clinical studies and daily practice. Additionally, scientific knowledge in hepatology is constantly evolving with, particularly, an increase in the field of non-alcoholic fatty liver disease which is considered today as the most frequent liver disease worldwide. In this review, we will describe scientific evidence for the effectiveness of silymarin in hepatic disorders. We will focus on silymarin’s pharmacological effects in non-alcoholic fatty liver disease and on its well described effects in alcoholic liver disease and acute intoxications, e.g. with Amanita species. We will discuss the relevance of pharmacological data as a function of doses or concentrations required for a given effect and of concentrations achieved in the target tissues. Many pharmacological effects of silymarin can be attributed to effects downstream or upstream of its antioxidative and membrane-stabilizing properties. However, despite promising new experimental and clinical data further clinical studies are required including long-term observations and the application of hard clinical endpoints such as survival rates, to further support silymarin’s use for the treatment of hepatic diseases.
81
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Jorge Henao‐Mejia, Eran Elinav, Chengcheng Jin et al. · Nature · 2012 · 2.4K citations
Life Sciences, Immunology, Pathology +12
Ramón Bataller · Journal of Clinical Investigation · 2005 · 1.5K citations · Full text
Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis
Ali A. Mokdad, Alan D López, Saied Shahraz et al. · BMC Medicine · 2014 · 1.1K citations · Full text